Driving factors boosting the Hepatocellular Carcinoma Market

The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies.

Opdivo, leading drug of Bristol-Myers Squibb approved only in the US and Stivarga developed by Bayer are the two FDA-approved Hepatocellular Carcinoma treatment drugs that have so far created a positive effect on HCC Market.

Hepatocellular Carcinoma Market Trends

The dynamics of Hepatocellular Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028, as estimated by DelveInsight.

The Hepatocellular Carcinoma emerging therapies that are going to impact the HCC market are Durvalumab plus Tremelimumab (AstraZeneca; as First-line for Advanced Hepatocellular Carcinoma); SHR-1210 (Jiangsu HengRui Medicine; first-line therapy in Advanced Hepatocellular Carcinoma) and BGB-A317 (BeiGene; First-Line Treatment for Unresectable Hepatocellular Carcinoma); ET140202 (Eureka Therapeutics) and many more.

Durvalumab plus Tremelimumab

AstraZeneca intends to file for Durvalumab plus Tremelimumab combination after 2020 in the G8 countries. Developing the combination of Durvalumab plus Tremelimumab, it will be treated as first-line therapy in Advanced Hepatocellular Carcinoma. Recently, the company has announced positive results of the ongoing Phase II trial of in patients with advanced hepatocellular carcinoma.

BGB-A317

Another Pharma giant, Beigene is developing BGB-A317 in Phase III as a First-Line Unresectable Hepatocellular Carcinoma Treatment. BGB-A317 works by activating and restoring T-cells’ ability to kill cancer cells. Activated T-cells are integral to the treatment of cancer as they help to kill malignant cells. As stated by the company, BGB-A317 is different from the existing and approved anti-PD-1 antibodies because of its high affinity and superior target specificity.

ET140202

ET140202 is another drug under clinical trials by Eureka Therapeutics. The company initiated the clinical trials of the drug for treating advanced hepatocellular carcinoma, the predominant type of liver cancer.

Apart from these, few other companies are conducting studies in order to test the efficacy of combination therapies for the advanced hepatocellular carcinoma treatment.

Other companies driving Hepatocellular Carcinoma therapy market

One such example is LSK BioPharma entered into a global clinical collaboration with advanced hepatocellular carcinoma patient pool, evaluating the safety and efficacy of LSKBioPharma’s rivoceranib.

There are other molecules as well in the early stage of development as well, which are expected to create a positive impact on the Hepatocellular carcinoma market revenue once they enter the market.

For Instance, Genoscience Pharma is currently running Phase Ib/IIa Clinical trial for its leading drug candidate, GNS561 in patients suffering from advanced HCC.

Overall, a robust pipeline filled with novel therapies along with the rising incidence of the disease will lead to a significant boost to the Hepatocellular carcinoma market revenue generated during the forecast period [2019-2028].